The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Header
News Archive
Showing 77 results
October 2026
-
Media Release
Novartis Canada Expands Multiple Sclerosis Education Through New MyRules.ca Resources and the My Krew Community Event
Approximately 90,000 Canadians live with multiple sclerosis (MS) 1, and Canada has one of the highest rates of MS in the world1.The My Krew Community Event will bring together Canadians affected… -
Media Release
INESSS recommends reimbursement of KISQALI® for all eligible patients with early-stage breast cancer at high risk of recurrence
Institut national d’excellence en santé et en services sociaux (INESSS) recommends reimbursement of KISQALI® (ribociclib tablets) for patients with stage II or III HR+ (hormone receptor–positive)/…
July 2026
-
Media Release
Novartis receives Health Canada approval for ᴾʳRHAPSIDO® (remibrutinib tablets) oral treatment for adults with CSU
RHAPSIDO® (remibrutinib tablets) is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. 1The phase III… -
Media Release
Novartis receives Health Canada approval for VANRAFIAᵀᴹ (atrasentan tablet) for proteinuria reduction in adults with primary immunoglobulin A nephropathy (IgAN)
VANRAFIATM (atrasentan tablets) is indicated to reduce proteinuria in adults with IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.1In the…
June 2026
-
Media Release
Novartis Canada and SP Quebec Celebrate 16 Years of Partnership Through Annual MS Tri-Challenge Fundraiser
The MS Tri-Challenge returns to Montreal on Saturday, September 12, 2026, at Parc Jean-Drapeau as part of the Sail Challenge Esprit de MontréalSince 2010, Novartis Canada has raised over $… -
Media Release
Novartis Canada and the pan-Canadian Pharmaceutical Alliance Achieve Milestone Agreement Enabling Public Reimbursement of (pr)Scemblix® (asciminib tablets)
MONTREAL, June 3, 2026 /CNW/ - Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance…
May 2026
-
Media Release
Novartis Canada Recognizes Next Generation of Oncology Innovators Through NOYCIA Awards at ASCO
MONTREAL, May 26, 2026 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to unveil the recipients of the 2026 Novartis Oncology Young Canadian Investigator Awards (NOYCIA),… -
Media Release
Novartis Canada launches third edition of its Health Equity Initiative, prioritizing Women’s Health
Montreal, May 14, 2026 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) today announces the third edition of its Health Equity Initiative, reaffirming its… -
Media Release
Novartis Canada Recognizes MS Awareness Month with the Third Annual My Krew Campaign
Approximately 90,000 Canadians live with multiple sclerosis (MS), a disease that impacts the central nervous system.1 Canada has one of the highest rates of MS in the world, with an average of 12… -
Media Release
Novartis receives Health Canada approval for ᴾͬ Fabhalta® oral treatment for adults with C3G
Fabhalta® (iptacopan capsules) is an oral Factor B inhibitor indicated for the treatment of adult patients with complement 3 glomerulopathy (C3G) to reduce proteinuria.1Phase III APPEAR-C3G…